RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2008-2014

ABSTRACT

The RESOLUTE-III Allcomers trial is a prospective, multicenter, randomized, two-arm, international, non-inferiority, open-label study with 2300 patients at 15-20 centers. The study is a "real world, all comers" study. Primary objective: to compare the Medtronic Endeavor-Resolute (Zotarolimus-Eluting stent) system with the Abbott XIENCE V (Everolimus-Eluting stent) system with respect to cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), Target Lesion Revascularization at 1 year in a "real world" patient population. Detailed Description The RESOLUTE-III Allcomers trial is a prospective, multicenter, randomized, two-arm, international, non-inferiority, open-label study with 2300 patients at 15-20 centers. The study is a "real world, all comers" study. Primary objective: to compare the Medtronic Endeavor-Resolute (Zotarolimus-Eluting stent) system with the Abbott XIENCE V (Everolimus-Eluting stent) system with respect to cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), Target Lesion Revascularization at 1 year in a "real world" patient population. Study hypothesis: To determine whether the Zotarolimus-Eluting stent (Medtronic Endeavor-Resolute) is non-inferior to the Everolimus-eluting stent (Abbott XIENCE V) in terms of the primary endpoint at 12 months after stent implantation. More... »

URL

https://clinicaltrials.gov/show/NCT00617084

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The RESOLUTE-III Allcomers trial is a prospective, multicenter, randomized, two-arm, international, non-inferiority, open-label study with 2300 patients at 15-20 centers. The study is a \"real world, all comers\" study. Primary objective: to compare the Medtronic Endeavor-Resolute (Zotarolimus-Eluting stent) system with the Abbott XIENCE V (Everolimus-Eluting stent) system with respect to cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), Target Lesion Revascularization at 1 year in a \"real world\" patient population.\n\nDetailed Description\nThe RESOLUTE-III Allcomers trial is a prospective, multicenter, randomized, two-arm, international, non-inferiority, open-label study with 2300 patients at 15-20 centers. The study is a \"real world, all comers\" study. Primary objective: to compare the Medtronic Endeavor-Resolute (Zotarolimus-Eluting stent) system with the Abbott XIENCE V (Everolimus-Eluting stent) system with respect to cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), Target Lesion Revascularization at 1 year in a \"real world\" patient population. Study hypothesis: To determine whether the Zotarolimus-Eluting stent (Medtronic Endeavor-Resolute) is non-inferior to the Everolimus-eluting stent (Abbott XIENCE V) in terms of the primary endpoint at 12 months after stent implantation.", 
    "endDate": "2014-02-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00617084", 
    "keywords": [
      "comer", 
      "randomized comparison", 
      "stent", 
      "percutaneous coronary intervention", 
      "trial", 
      "multicenter", 
      "two-arm", 
      "non-inferiority", 
      "open-label study", 
      "patient", 
      "real world", 
      "primary objective", 
      "endeavor", 
      "Abbott", 
      "respect", 
      "death", 
      "myocardial infarction", 
      "target", 
      "target lesion", 
      "patient population", 
      "study hypothesis", 
      "non-inferior", 
      "primary endpoint", 
      "stent implantation"
    ], 
    "name": "RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00617084"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00005.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.5645.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.419673.e", 
        "type": "Organization"
      }
    ], 
    "startDate": "2008-04-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1161/circinterventions.114.002279", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000604461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jcin.2013.04.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001751684"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jcin.2011.01.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006869474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/heartjnl-2012-302267", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010617819"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circinterventions.115.003255", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014803484"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehu026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015239381"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1004130", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015896205"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jcin.2012.11.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018365029"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.110.014514", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023641324"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ahj.2013.04.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024798611"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circinterventions.114.002230", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024938186"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/heartjnl-2012-303368", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027717541"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ahj.2011.09.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028813831"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehr182", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029358132"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jcin.2011.11.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031726943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jacc.2011.01.036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033852967"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circinterventions.111.965301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039096085"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)60395-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042490154"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jacc.2013.12.036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042970951"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10554-015-0631-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044578761", 
          "https://doi.org/10.1007/s10554-015-0631-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehv227", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047743111"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00617084"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00617084'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00617084'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00617084'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00617084'


 

This table displays all metadata directly associated to this object as RDF triples.

109 TRIPLES      16 PREDICATES      61 URIs      33 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00617084 schema:about anzsrc-for:3048
2 schema:description The RESOLUTE-III Allcomers trial is a prospective, multicenter, randomized, two-arm, international, non-inferiority, open-label study with 2300 patients at 15-20 centers. The study is a "real world, all comers" study. Primary objective: to compare the Medtronic Endeavor-Resolute (Zotarolimus-Eluting stent) system with the Abbott XIENCE V (Everolimus-Eluting stent) system with respect to cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), Target Lesion Revascularization at 1 year in a "real world" patient population. Detailed Description The RESOLUTE-III Allcomers trial is a prospective, multicenter, randomized, two-arm, international, non-inferiority, open-label study with 2300 patients at 15-20 centers. The study is a "real world, all comers" study. Primary objective: to compare the Medtronic Endeavor-Resolute (Zotarolimus-Eluting stent) system with the Abbott XIENCE V (Everolimus-Eluting stent) system with respect to cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), Target Lesion Revascularization at 1 year in a "real world" patient population. Study hypothesis: To determine whether the Zotarolimus-Eluting stent (Medtronic Endeavor-Resolute) is non-inferior to the Everolimus-eluting stent (Abbott XIENCE V) in terms of the primary endpoint at 12 months after stent implantation.
3 schema:endDate 2014-02-01T00:00:00Z
4 schema:keywords Abbott
5 comer
6 death
7 endeavor
8 multicenter
9 myocardial infarction
10 non-inferior
11 non-inferiority
12 open-label study
13 patient
14 patient population
15 percutaneous coronary intervention
16 primary endpoint
17 primary objective
18 randomized comparison
19 real world
20 respect
21 stent
22 stent implantation
23 study hypothesis
24 target
25 target lesion
26 trial
27 two-arm
28 schema:name RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention
29 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00617084
30 schema:sdDatePublished 2019-03-07T15:22
31 schema:sdLicense https://scigraph.springernature.com/explorer/license/
32 schema:sdPublisher Nbd69619c45f74e8fb88c5f637f856183
33 schema:sponsor https://www.grid.ac/institutes/grid.419673.e
34 https://www.grid.ac/institutes/grid.5645.2
35 schema:startDate 2008-04-01T00:00:00Z
36 schema:subjectOf sg:pub.10.1007/s10554-015-0631-0
37 https://doi.org/10.1016/j.ahj.2011.09.010
38 https://doi.org/10.1016/j.ahj.2013.04.001
39 https://doi.org/10.1016/j.jacc.2011.01.036
40 https://doi.org/10.1016/j.jacc.2013.12.036
41 https://doi.org/10.1016/j.jcin.2011.01.008
42 https://doi.org/10.1016/j.jcin.2011.11.011
43 https://doi.org/10.1016/j.jcin.2012.11.006
44 https://doi.org/10.1016/j.jcin.2013.04.017
45 https://doi.org/10.1016/s0140-6736(11)60395-4
46 https://doi.org/10.1056/nejmoa1004130
47 https://doi.org/10.1093/eurheartj/ehr182
48 https://doi.org/10.1093/eurheartj/ehu026
49 https://doi.org/10.1093/eurheartj/ehv227
50 https://doi.org/10.1136/heartjnl-2012-302267
51 https://doi.org/10.1136/heartjnl-2012-303368
52 https://doi.org/10.1161/circinterventions.111.965301
53 https://doi.org/10.1161/circinterventions.114.002230
54 https://doi.org/10.1161/circinterventions.114.002279
55 https://doi.org/10.1161/circinterventions.115.003255
56 https://doi.org/10.1161/circulationaha.110.014514
57 schema:url https://clinicaltrials.gov/show/NCT00617084
58 sgo:license sg:explorer/license/
59 sgo:sdDataset clinical_trials
60 rdf:type schema:MedicalStudy
61 Nbd69619c45f74e8fb88c5f637f856183 schema:name Springer Nature - SN SciGraph project
62 rdf:type schema:Organization
63 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
64 rdf:type schema:DefinedTerm
65 sg:pub.10.1007/s10554-015-0631-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044578761
66 https://doi.org/10.1007/s10554-015-0631-0
67 rdf:type schema:CreativeWork
68 https://doi.org/10.1016/j.ahj.2011.09.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028813831
69 rdf:type schema:CreativeWork
70 https://doi.org/10.1016/j.ahj.2013.04.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024798611
71 rdf:type schema:CreativeWork
72 https://doi.org/10.1016/j.jacc.2011.01.036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033852967
73 rdf:type schema:CreativeWork
74 https://doi.org/10.1016/j.jacc.2013.12.036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042970951
75 rdf:type schema:CreativeWork
76 https://doi.org/10.1016/j.jcin.2011.01.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006869474
77 rdf:type schema:CreativeWork
78 https://doi.org/10.1016/j.jcin.2011.11.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031726943
79 rdf:type schema:CreativeWork
80 https://doi.org/10.1016/j.jcin.2012.11.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018365029
81 rdf:type schema:CreativeWork
82 https://doi.org/10.1016/j.jcin.2013.04.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001751684
83 rdf:type schema:CreativeWork
84 https://doi.org/10.1016/s0140-6736(11)60395-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042490154
85 rdf:type schema:CreativeWork
86 https://doi.org/10.1056/nejmoa1004130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015896205
87 rdf:type schema:CreativeWork
88 https://doi.org/10.1093/eurheartj/ehr182 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029358132
89 rdf:type schema:CreativeWork
90 https://doi.org/10.1093/eurheartj/ehu026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015239381
91 rdf:type schema:CreativeWork
92 https://doi.org/10.1093/eurheartj/ehv227 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047743111
93 rdf:type schema:CreativeWork
94 https://doi.org/10.1136/heartjnl-2012-302267 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010617819
95 rdf:type schema:CreativeWork
96 https://doi.org/10.1136/heartjnl-2012-303368 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027717541
97 rdf:type schema:CreativeWork
98 https://doi.org/10.1161/circinterventions.111.965301 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039096085
99 rdf:type schema:CreativeWork
100 https://doi.org/10.1161/circinterventions.114.002230 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024938186
101 rdf:type schema:CreativeWork
102 https://doi.org/10.1161/circinterventions.114.002279 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000604461
103 rdf:type schema:CreativeWork
104 https://doi.org/10.1161/circinterventions.115.003255 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014803484
105 rdf:type schema:CreativeWork
106 https://doi.org/10.1161/circulationaha.110.014514 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023641324
107 rdf:type schema:CreativeWork
108 https://www.grid.ac/institutes/grid.419673.e schema:Organization
109 https://www.grid.ac/institutes/grid.5645.2 schema:Organization
 




Preview window. Press ESC to close (or click here)


...